Victoza® helps lower the risk of major cardiovascular events. Talk to your health care provider about how Victoza® not only lowers A1C, but also reduces the risk of major CV events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.

A new study shows that semaglutide reduces heart failure symptoms like fatigue and swelling by bringing down body weight.

Though it is effective in controlling blood sugar, Victoza may be linked to dangerous side effects, including pancreatitis and thyroid cancer.

For the reduction of cardiovascular risk, a GLP-1 RA with proven cardiovascular benefit should be used; this group includes liraglutide, semaglutide subcutaneously, and dulaglutide (albiglutide and efpeglenatide are currently not available in the United States or European Union).

Ozempic®, along with diet and exercise, is proven to improve blood sugar in adults with type 2 diabetes. In adults with type 2 diabetes and known heart disease, Ozempic® reduces the risk of major cardiovascular events such as stroke, heart attack, or death. You may also lose some weight.

OZEMPIC® is not recommended for use in patients with end-stage renal disease. Heart Rate Increase: OZEMPIC® causes an increase in heart rate (see ACTION AND CLINICAL PHARMACOLOGY, Cardiac Electrophysiology).

You can stay on Victoza for as long as your healthcare provider recommends. There is no official time limit for using Victoza. Rather, it is based on how well you tolerate the side effects and whether you continue to see health benefits. In one clinical trial, 16% of people dropped out due to Victoza's side effects.

Why was Victoza taken off the market? As with all medications, health benefits may outweigh certain risks. In 2013, the FDA investigated Victoza after claims it may increase the risk of pancreatic cancer. The drug manufacturer has since placed a black box warning on the drug warning consumers about potential dangers.

Glp-1 Ras and Coronary Ischaemia. A great many preclinical and clinical studies show that the GLP-1 RAs have a cardioprotective effect.

All studies showed that GLP-1 RA significantly caused weight loss and improved cardiac functional capacity by increasing left ventricular ejection fraction and reducing end-systolic and end-diastolic left ventricle volume. GLP-1 RA also improved myocardial blood flow without affecting myocardial glucose uptake.

Are there cardiovascular impacts for people with and without diabetes? The FDA has affirmed the cardiovascular benefits of semaglutide for those with type 2 diabetes and heart disease.

Subcutaneous once-weekly semaglutide 2.4 mg, a GLP1 receptor agonist, was associated with a statistically significant 20% reduction in major adverse cardiovascular events (MACE) compared with placebo, according to top line results from the randomized, double-blind SELECT trial reported in an Aug. 8 press release.